|
WO1997046256A1
(en)
*
|
1996-05-23 |
1997-12-11 |
The Scripps Research Institute |
Mhc class ii antigen-presenting systems and methods for activating cd4+ t cells
|
|
US6291430B1
(en)
*
|
1997-09-12 |
2001-09-18 |
Ludwig Institute For Cancer Research |
Mage-3 peptides presented by HLA class II molecules
|
|
US6576428B1
(en)
|
1998-05-11 |
2003-06-10 |
Miltenyi Biotech Gmbh |
Direct selection of antigen-specific T cells, compositions obtained thereby and methods of use thereof
|
|
US6230662B1
(en)
|
1998-06-22 |
2001-05-15 |
Theresa Miale |
Animal lift and transport apparatus and method for using the same
|
|
EP1104456A1
(en)
*
|
1998-08-10 |
2001-06-06 |
Chiron Corporation |
Engineered antigen-presenting cells expressing an array of antigens and uses thereof
|
|
US7807377B2
(en)
|
1998-10-20 |
2010-10-05 |
Salvatore Albani |
Method of isolating antigen-specific T cells employing artificial antigen presenting cells
|
|
US7022483B1
(en)
|
1998-10-20 |
2006-04-04 |
Salvatore Albani |
Methods for identifying and isolating antigen-specific T cells
|
|
US6225443B1
(en)
*
|
1999-05-19 |
2001-05-01 |
Wisconsin Alumni Research Foundation |
Cytotoxic T lymphocyte epitopes of the major outer membrane protein of chlamydia trachomatis
|
|
US7521202B2
(en)
|
1999-12-17 |
2009-04-21 |
The Board Of Regents Of The University Of Oklahoma |
Method and apparatus for the production of soluble MHC antigens and uses thereof
|
|
DE10009341A1
(de)
*
|
2000-02-22 |
2001-09-06 |
Florian Kern |
Verfahren zur antigen-spezifischen Stimulation von T-Lymphozyten
|
|
US7541184B2
(en)
*
|
2000-02-24 |
2009-06-02 |
Invitrogen Corporation |
Activation and expansion of cells
|
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
|
AU2000243137A1
(en)
*
|
2000-04-20 |
2001-11-07 |
Salvatore Albani |
Methods for isolation, quantification, characterization and modulation of antigen-specific t cells
|
|
WO2002030964A2
(en)
|
2000-10-10 |
2002-04-18 |
The Board Of Regents Of The University Of Oklahoma |
Comparative ligand mapping from mhc positive cells
|
|
US20070026433A1
(en)
|
2001-03-09 |
2007-02-01 |
Hildebrand William H |
Epitope testing using soluble HLA
|
|
WO2002056908A2
(en)
*
|
2001-01-16 |
2002-07-25 |
Hildebrand William H |
Artificial antigen-presenting cells
|
|
AU2002255532A1
(en)
*
|
2001-02-13 |
2002-10-15 |
Joseph D. Mosca |
Biological carriers for induction of immune responses
|
|
US20040071671A1
(en)
*
|
2001-02-20 |
2004-04-15 |
Leturcq Didier J. |
Cell therapy method for the treatment of tumors
|
|
HUP0402656A3
(en)
*
|
2001-02-20 |
2012-03-28 |
Ortho Mcneil Pharm Inc |
A cell therapy method for the treatment of tumors
|
|
FR2824567B1
(fr)
*
|
2001-05-11 |
2003-08-08 |
Inst Nat Sante Rech Med |
Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene
|
|
WO2003057171A2
(en)
*
|
2002-01-03 |
2003-07-17 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of t-cells using an engineered multivalent signaling platform
|
|
US7638326B2
(en)
|
2002-01-03 |
2009-12-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform
|
|
US7745140B2
(en)
*
|
2002-01-03 |
2010-06-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
|
|
US20040072262A1
(en)
*
|
2002-10-11 |
2004-04-15 |
Montero-Julian Felix A. |
Methods and systems for detecting MHC class I binding peptides
|
|
DE60218173T2
(de)
|
2002-10-11 |
2007-11-22 |
Sentoclone Ab |
Immuntherapie für Krebs
|
|
US7435592B2
(en)
|
2003-05-13 |
2008-10-14 |
Immunovative Therapies, Ltd. |
Compositions for allogeneic cell therapy
|
|
US20050095655A1
(en)
*
|
2003-11-03 |
2005-05-05 |
Montero-Julian Felix A. |
Solution-based methods for detecting MHC-binding peptides
|
|
US7592431B2
(en)
|
2004-02-26 |
2009-09-22 |
Immunovative Therapies, Ltd. |
Biodegradable T-cell Activation device
|
|
LT2573166T
(lt)
|
2004-02-26 |
2016-09-26 |
Immunovative Therapies, Ltd. |
T ląstelių paruošimo būdas ląstelių terapijai
|
|
WO2005111624A2
(en)
*
|
2004-05-07 |
2005-11-24 |
Beckman Coulter, Inc. |
Mhc bridging system for detecting ctl-mediated lysis of antigen presenting cells
|
|
EP2295588B1
(en)
|
2004-05-27 |
2018-03-07 |
The Trustees Of The University Of Pennsylvania |
Novel artificial antigen presenting cells and uses thefor
|
|
US7678379B2
(en)
*
|
2004-06-17 |
2010-03-16 |
Beckman Coulter, Inc. |
Mycobacterium tuberculosis epitopes and methods of use thereof
|
|
EP1712615A1
(en)
*
|
2005-04-15 |
2006-10-18 |
Txcell |
In vitro production of a cell population using feeder cells
|
|
US8652465B2
(en)
|
2005-06-08 |
2014-02-18 |
Emory University |
Methods and compositions for the treatment of persistent infections
|
|
US20100080792A1
(en)
*
|
2005-06-16 |
2010-04-01 |
Dorothee Herlyn |
Method for Identifying a MHC Class II-Dependent Tumor-Associated T Helper Cell Antigen
|
|
WO2007071389A1
(en)
|
2005-12-21 |
2007-06-28 |
Sentoclone Ab |
Method for treating disseminated cancer
|
|
JP5244610B2
(ja)
|
2005-12-21 |
2013-07-24 |
セントクローネ インターナショナル エービー |
ガン患者の免疫療法用腫瘍反応性ｔリンパ球の改良拡大法
|
|
US8211424B2
(en)
|
2005-12-21 |
2012-07-03 |
Sentoclone International Ab |
Method for treating malignant melanoma
|
|
US8101173B2
(en)
|
2005-12-21 |
2012-01-24 |
Sentoclone International Ab |
Method for treating urinary bladder cancer
|
|
MX2008011302A
(es)
|
2006-03-01 |
2008-11-04 |
Janssen Pharmaceutica Nv |
Tratamiento de cancer que combina agente de linfodeplecion con linfocitos t citotoxicos y citocinas.
|
|
WO2008045286A2
(en)
|
2006-10-04 |
2008-04-17 |
Janssen Pharmaceutica N.V. |
Preparation of inactivated artificial antigen presenting cells and their use in cell therapies
|
|
HUE030139T2
(en)
*
|
2006-12-27 |
2017-04-28 |
Univ Emory |
Compositions and methods for the treatment of infections
|
|
US20120034155A1
(en)
*
|
2010-08-03 |
2012-02-09 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Artificial cells
|
|
US9598491B2
(en)
*
|
2008-11-28 |
2017-03-21 |
Emory University |
Methods for the treatment of infections and tumors
|
|
US8075895B2
(en)
|
2009-09-22 |
2011-12-13 |
Janssen Pharmaceutica N.V. |
Identification of antigenic peptides from multiple myeloma cells
|
|
EP2404618A1
(en)
|
2010-07-07 |
2012-01-11 |
Stichting Katholieke Universiteit meer in het bijzonder Radboud Universiteit Nijmegen |
Immunomodulatory protein constructs with a helical polymeric backbone.
|
|
AU2011287108B2
(en)
*
|
2010-08-06 |
2014-08-28 |
Canine-Lab.Inc. |
Immunological function enhancing agent
|
|
DK2704741T3
(da)
|
2011-05-03 |
2017-11-27 |
Immunovative Therapies Ltd |
Fremgangsmåder til håndtering af biologiske lægemidler indeholdende levende celler
|
|
EP2704732B1
(en)
|
2011-05-03 |
2020-03-04 |
Immunovative Therapies, Ltd. |
Induction of il-12 using immunotherapy
|
|
US9260696B2
(en)
|
2012-04-24 |
2016-02-16 |
Dan S. Kaufman |
Method for developing natural killer cells from stem cells
|
|
KR102452767B1
(ko)
|
2013-05-14 |
2022-10-12 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
가공된 키메라 항원 수용체 (ｃａｒ) ｔ-세포의 인간 적용
|
|
ES2899078T3
(es)
|
2013-12-16 |
2022-03-10 |
The Us Secretary Dept Of Health & Human Services Office Of Technology Transfer |
Inmunoterapia contra el cáncer mediante el suministro de antígenos de MHC de clase II y una proteína de señal coestimuladora utilizando un replicón de partículas similares a un virus
|
|
EP3105335B1
(en)
|
2014-02-14 |
2019-10-02 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors and methods of making
|
|
US10857219B2
(en)
|
2014-03-28 |
2020-12-08 |
The Board Of Regents Of The University Of Oklahoma |
Compositions comprising soluble HLA/M. tuberculosis-specific ligand complexes and methods of production and use thereof
|
|
CN106459924A
(zh)
|
2014-04-23 |
2017-02-22 |
得克萨斯州大学系统董事会 |
用于疗法中的嵌合抗原受体(car)及其制备方法
|
|
AU2015249371B2
(en)
|
2014-04-24 |
2020-04-30 |
Board Of Regents, The University Of Texas System |
Application of induced pluripotent stem cells to generate adoptive cell therapy products
|
|
EP3215535A2
(en)
|
2014-11-05 |
2017-09-13 |
Board of Regents, The University of Texas System |
Gene modified immune effector cells and engineered cells for expansion of immune effector cells
|
|
US10570186B2
(en)
|
2014-11-05 |
2020-02-25 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors (CAR) to selectively target protein complexes
|
|
FR3031519B1
(fr)
|
2015-01-14 |
2016-12-30 |
Arkema France |
Composition a base de terpolymere electroactif
|
|
AU2016232280B2
(en)
*
|
2015-03-16 |
2018-05-31 |
Helmholtz Zentrum München-Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) |
Method of detecting new immunogenic T cell epitopes and isolating new antigen-specific T cell receptors by means of an MHC cell library
|
|
EP3368075B1
(en)
|
2015-10-27 |
2020-01-29 |
Board of Regents, The University of Texas System |
Chimeric antigen receptor molecules and uses thereof
|
|
IL321834A
(en)
|
2016-06-08 |
2025-08-01 |
Precigen Inc |
Cd33 specific chimeric antigen receptors
|
|
MA45784A
(fr)
|
2016-07-29 |
2019-06-05 |
Juno Therapeutics Inc |
Anticorps anti-idiotypes dirigés contre anti-cd19 anticorps
|
|
EP3538112A4
(en)
|
2016-11-09 |
2020-09-02 |
Musc Foundation for Research Development |
CD38-NAD + REGULATED METABOLIC AXIS IN ANTITUMOR IMMUNOTHERAPY
|
|
AU2018207281B2
(en)
|
2017-01-10 |
2024-08-01 |
Precigen, Inc. |
Modulating expression of polypeptides via new gene switch expression systems
|
|
US11285196B2
(en)
|
2017-03-13 |
2022-03-29 |
Eslam Abbas Baseuny |
Multivalent biologic constructs for inducing a therapeutic modulation of cellular response and uses thereof
|
|
EP4083063A3
(en)
|
2017-04-18 |
2023-01-04 |
FUJIFILM Cellular Dynamics, Inc. |
Antigen-specific immune effector cells
|
|
CA3065930A1
(en)
|
2017-06-07 |
2018-12-13 |
Intrexon Corporation |
Expression of novel cell tags
|
|
CA3081336A1
(en)
|
2017-10-12 |
2019-04-18 |
Gregory LIZEE |
T cell receptors for immunotherapy
|
|
US12473336B2
(en)
|
2018-02-21 |
2025-11-18 |
Board Of Regents, The University Of Texas System |
Methods for activation and expansion of natural killer cells and uses thereof
|
|
WO2020113029A2
(en)
|
2018-11-28 |
2020-06-04 |
Board Of Regents, The University Of Texas System |
Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
|
|
CN113316455A
(zh)
|
2018-11-29 |
2021-08-27 |
得克萨斯大学体系董事会 |
用于离体扩增自然杀伤细胞的方法及其用途
|
|
JP2023500671A
(ja)
|
2019-11-06 |
2023-01-10 |
ベイラー カレッジ オブ メディスン |
がんのｔ細胞治療のための細胞傷害性エフェクターメモリーｔ細胞の産生方法
|
|
US20230079539A1
(en)
|
2020-02-10 |
2023-03-16 |
Board Of Regents, The University Of Texas System |
Methods for rapid cloning and expression of hla class i cells
|
|
IL298558A
(en)
|
2020-05-27 |
2023-01-01 |
Antion Biosciences Sa |
Adapter molecules redirect CAR T cells to the antigen of interest
|
|
US12275766B2
(en)
|
2020-12-23 |
2025-04-15 |
Janssen Biotech, Inc. |
Neoantigen peptide mimics
|
|
WO2023211972A1
(en)
|
2022-04-28 |
2023-11-02 |
Medical University Of South Carolina |
Chimeric antigen receptor modified regulatory t cells for treating cancer
|